Literature DB >> 28662962

Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.

Yan Xiong1, Fengling Li2, Nicolas Babault1, Hong Wu2, Aiping Dong2, Hong Zeng2, Xin Chen1, Cheryl H Arrowsmith3, Peter J Brown2, Jing Liu1, Masoud Vedadi4, Jian Jin5.   

Abstract

Given the high homology between the protein lysine methyltransferases G9a-like protein (GLP) and G9a, it has been challenging to develop potent and selective inhibitors for either enzyme. Recently, we reported two quinazoline compounds, MS0124 and MS012, as GLP selective inhibitors. To further investigate the structure-activity relationships (SAR) of the quinazoline scaffold, we designed and synthesized a range of analogs bearing different 2-amino substitutions and evaluated their inhibition potencies against both GLP and G9a. These studies led to the identification of two new GLP selective inhibitors, 13 (MS3748) and 17 (MS3745), with 59- and 65-fold higher potency for GLP over G9a, which were confirmed by isothermal titration calorimetry (ITC). Crystal structures of GLP and G9a in complex with 13 and 17 provide insight into the interactions of the inhibitors with both proteins. In addition, we generated GLP selective inhibitors bearing a quinoline core instead of the quinazoline core.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  G9a; GLP; Inhibitor; Quinazoline; Quinoline

Mesh:

Substances:

Year:  2017        PMID: 28662962      PMCID: PMC5562403          DOI: 10.1016/j.bmc.2017.06.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  51 in total

Review 1.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

2.  Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.

Authors:  Wei-Lin Chen; Zhi-Hui Wang; Tao-Tao Feng; Dong-Dong Li; Chu-Hui Wang; Xiao-Li Xu; Xiao-Jin Zhang; Qi-Dong You; Xiao-Ke Guo
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

3.  Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome.

Authors:  Yuna Kim; Hyeong-Min Lee; Yan Xiong; Noah Sciaky; Samuel W Hulbert; Xinyu Cao; Jeffrey I Everitt; Jian Jin; Bryan L Roth; Yong-Hui Jiang
Journal:  Nat Med       Date:  2016-12-26       Impact factor: 53.440

4.  Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase.

Authors:  Debasis Patnaik; Hang Gyeong Chin; Pierre-Olivier Estève; Jack Benner; Steven E Jacobsen; Sriharsa Pradhan
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

5.  Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex.

Authors:  Anne Schaefer; Srihari C Sampath; Adam Intrator; Alice Min; Tracy S Gertler; D James Surmeier; Alexander Tarakhovsky; Paul Greengard
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

6.  Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D.

Authors:  Thomas Weiss; Sonja Hergeth; Ulrike Zeissler; Annalisa Izzo; Philipp Tropberger; Barry M Zee; Miroslav Dundr; Benjamin A Garcia; Sylvain Daujat; Robert Schneider
Journal:  Epigenetics Chromatin       Date:  2010-03-24       Impact factor: 4.954

7.  Protein lysine methyltransferase G9a acts on non-histone targets.

Authors:  Philipp Rathert; Arunkumar Dhayalan; Marie Murakami; Xing Zhang; Raluca Tamas; Renata Jurkowska; Yasuhiko Komatsu; Yoichi Shinkai; Xiaodong Cheng; Albert Jeltsch
Journal:  Nat Chem Biol       Date:  2008-04-27       Impact factor: 15.040

8.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.

Authors:  Yanqi Chang; Xing Zhang; John R Horton; Anup K Upadhyay; Astrid Spannhoff; Jin Liu; James P Snyder; Mark T Bedford; Xiaodong Cheng
Journal:  Nat Struct Mol Biol       Date:  2009-02-15       Impact factor: 15.369

9.  Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a.

Authors:  Nitipol Srimongkolpithak; Sandeep Sundriyal; Fengling Li; Masoud Vedadi; Matthew J Fuchter
Journal:  Medchemcomm       Date:  2014-09-11       Impact factor: 3.597

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.

Authors:  Kwang-Su Park; Yan Xiong; Hyerin Yim; Julia Velez; Nicolas Babault; Prashasti Kumar; Jing Liu; Jian Jin
Journal:  J Med Chem       Date:  2022-06-28       Impact factor: 8.039

2.  Development of a Photo-Cross-Linkable Diaminoquinazoline Inhibitor for Target Identification in Plasmodium falciparum.

Authors:  Alexandra S Lubin; Ainoa Rueda-Zubiaurre; Holly Matthews; Hella Baumann; Fabio R Fisher; Julia Morales-Sanfrutos; Kate S Hadavizadeh; Flore Nardella; Edward W Tate; Jake Baum; Artur Scherf; Matthew J Fuchter
Journal:  ACS Infect Dis       Date:  2018-02-05       Impact factor: 5.084

3.  Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design.

Authors:  M Ramya Chandar Charles; Mu-Chun Li; Hsing-Pang Hsieh; Mohane Selvaraj Coumar
Journal:  ACS Omega       Date:  2021-02-22

4.  Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors.

Authors:  Chiara Luise; Dina Robaa; Pierre Regenass; David Maurer; Dmytro Ostrovskyi; Ludwig Seifert; Johannes Bacher; Teresa Burgahn; Tobias Wagner; Johannes Seitz; Holger Greschik; Kwang-Su Park; Yan Xiong; Jian Jin; Roland Schüle; Bernhard Breit; Manfred Jung; Wolfgang Sippl
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.